Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The present disclosure relates to a continuous process for impregnating active pharmaceutical ingredients (API) onto porous carriers, including the steps of introducing a porous carrier into a first feeder; continuously directing the porous carrier from the first feeder into a continuous blender, wherein the continuous blender comprises one or more nozzles; continuously introducing a solution comprising an API dissolved in solvent into the continuous blender through the one or more nozzles to form API-impregnated porous carrier; and continuously drying the API-impregnated porous carrier using a fluidized bed dryer to form a powder. The present disclosure also relates to a continuous process for manufacturing pharmaceutical drug products using continuously manufactured API-impregnated porous carriers. The present disclosure also relates to a continuous pharmaceutical drug manufacturing process that includes API-impregnated porous carriers as a raw material.

A method for producing powderized cannabis oil, powderized cannabis oil, and edible products and beverages comprising the powderized cannabis oil. Powderized cannabis oil contains cannabis oil and maltodextrin in a ratio of at least three grams of maltodextrin for every one-eighth of a gram of cannabis oil. Edible products and beverages incorporating the powderized cannabis oil are human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil providing CBD, THC and/or THCA.

This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.

The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.

Solid solution of gum arabic and at least one liposoluble active ingredient having particles of a size of less than 100 .Math.m and a weight ratio of gum arabic to liposoluble active ingredients of 5:1 to 200:1, obtainable by drying an aqueous solution of gum arabic to achieve a fine-particle dry product; admixing the dry product with a solution or dispersion of the liposoluble active ingredient(s) in an anhydrous solvent in which gum arabic is insoluble; mixing in the solution while homogenizing and further comminuting the dry product to a particle size of less than 100 .Math.m; and removing the solvent at a temperature of less than 70° C., as well as method for the preparation of the solution and the aqueous suspension containing it.

Viral epidemic infections due to influenza, or coronaviruses, particularly influenza A and SARS-CoV-1 and -2 virus cause significant morbidity and mortality. The significant mutation rate of this group of viruses renders existing vaccines or antiviral drugs often useless, creating a need for broad acting, viral DNA or RNA sequence independent antiviral drugs. This invention describes the repurposing of methylene blue and riboflavin, two FDA approved drugs with an excellent safety profile. Using a virus neutralization assay of H1N1 Influenza A and SARS-CoV-2, the significant viricidal activity of both drugs at pharmacological dose and under physiological conditions is demonstrated. In vivo prophylactic and therapeutic use of the drugs for anti-viral application in an animal model is described.

A synergistic non-toxic formulation for management of respiratory pathogens including coronaviruses and the process of preparing the synergistic formulation. The effective, non-toxic composition comprises of biological peptides including calcium chelating peptide and zinc chelating peptides, protease inhibitor such as 9-Arginine-peptide and inhibitor of viral replication enzyme such as vitamin B12 to reduce the presence of respiratory viruses including coronaviruses. The formulation is a cocktail of ingredients having a synergistic effect which is capable of being administered through various means including by way of inhalation, as nasal spray or an oral pump or via nebulizer to inhibit the entry and replication of respiratory pathogens. The combination of the formulation is such that it can be customized for a number of viral infections. The formulation is economical, self-administrable and effective even in low doses.